keyword
MENU ▼
Read by QxMD icon Read
search

Diffuse Large B cell lymphoma

keyword
https://www.readbyqxmd.com/read/29137822/dnmt1-is-associated-with-cell-cycle-and-dna-replication-gene-sets-in-diffuse-large-b-cell-lymphoma
#1
Suet Kee Loo, Suzina Sheikh Ab Hamid, Mustaffa Musa, Kah Keng Wong
Dysregulation of DNA (cytosine-5)-methyltransferase 1 (DNMT1) is associated with the pathogenesis of various types of cancer. It has been previously shown that DNMT1 is frequently expressed in diffuse large B-cell lymphoma (DLBCL), however its functions remain to be elucidated in the disease. In this study, we gene expression profiled (GEP) shRNA targeting DNMT1(shDNMT1)-treated germinal center B-cell-like DLBCL (GCB-DLBCL)-derived cell line (i.e. HT) compared with non-silencing shRNA (control shRNA)-treated HT cells...
October 9, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29137222/pi3k%C3%AE-inhibition-causes-feedback-activation-of-pi3k%C3%AE-in-the-abc-subtype-of-diffuse-large-b-cell-lymphoma
#2
Georgios N Pongas, Christina M Annunziata, Louis M Staudt
Cell line models of the activated B cell-like (ABC) subtype of diffuse large B cell (DLBCL) depend on both NF-κB and phosphatidylinositol 3-kinase (PI3K) signaling pathways for survival, especially those with gain-of-function B cell receptor (BCR) mutations. Here we show that these cells depend specifically on the PI3Kδ isoform, but that PI3K pathway interruption by PI3Kδ inhibitors is short-lived due to feedback activation of the PI3Kα isoform. PI3Kδ and PI3Kα inhibition cooperated in killing ABC DLBCL lines, and genetic knockdown of PI3Kα sensitized cells to PI3Kδ inhibition and prolonged the interruption of PI3K signaling...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137104/tumor-and-bone-marrow-uptakes-on-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-predict-prognosis-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-rituximab-containing-chemotherapy
#3
Chin-Chuan Chang, Shih-Feng Cho, Hung-Pin Tu, Chia-Yang Lin, Ya-Wen Chuang, Shu-Min Chang, Wen-Ling Hsu, Ying-Fong Huang
The purpose of this study was to determine the relevance of standardized uptake value (SUV) on [F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), focusing on tumor and bone marrow, to disease outcomes based on progression-free survival (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-containing chemotherapy.We reviewed the records of patients with DLBCL who were diagnosed between September 2009 and January 2013 and underwent pretreatment whole-body FDG PET/CT scans...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137041/efficacy-of-rituximab-combined-with-chop-for-treating-patients-with-diffuse-large-b-cell-lymphoma
#4
Xin Hu, Min Zeng, Shun-E Yang, Xiao Liang, Shan-Shan Ding, Li Guo, Shan Li, Shu-Juan Wen
BACKGROUND: This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 144 patients with DLBCL were randomly divided into intervention group and control group, 72 patients in each group. The patients in the control group received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, while the participants in the intervention group received R-CHOP...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29136714/-the-prognostic-significance-of-plasma-epstein-barr-virus-dna-in-patients-with-diffuse-large-b-cell-lymphoma
#5
N An, Y P Xie, Y Xu, P F Shi, S X Qian
To retrospectively analyze the prognostic significance of plasma Epstein-Barr virus (EBV) DNA in 122 patients with diffuse large B cell lymphoma (DLBCL). Plasma EBV DNA positivity was related to advanced disease stage (P=0.030), B symptoms (P=0.004) and elevated serum lactic dehydrogenase (LDH) (P=0.001). Furthermore, univariate analysis indicated that plasma EBV DNA level was associated with worse overall survival (OS) (HR=0.223, 95%CI 0.096-0.518, P<0.001) and worse progression free survival (PFS) (HR=4...
November 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29136691/-tumors-of-lymphoid-and-hematopoietic-tissue-of-spleen-a-clinicopathologic-analysis-of-53-cases
#6
D B Chen, D H Shen, H Zhang, Y Wang, Q J Song, S M Yang, X Z Fang
Objective: To study the clinicopathologic features, diagnosis and differential diagnosis of the tumors of lymphoidand hematopoietic tissue of the spleen(TLTS). Methods: Fifty-three cases of TLTS were selected from the pathologic files from Peking University People's Hospital from April 2002 to April 2017. According to WHO classification of tumors of hematopoietic and lymphoid tissues (2008) and its updated classification (2016), the cases were studied by microscopy, immunohistochemistry and in situ hybridization, combined with the bone marrow biopsy and clinical examination...
November 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29135973/hdac6-regulates-microrna-27b-that-suppresses-proliferation-promotes-apoptosis-and-target-met-in-diffuse-large-b-cell-lymphoma
#7
Y J Jia, Z B Liu, W G Wang, C B Sun, P Wei, Y L Yang, M J You, B H Yu, X Q Li, X Y Zhou
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Histone deacetylase 6 (HDAC6) is frequently altered in DLBCL and inhibition of HDAC6 has potent anti-tumor effects in vitro and in vivo. We profiled miRNAs that altered in the HDAC6 knockdown DLBCL cells with NanoString nCounter assay and identified microRNA-27b (miR-27b) as the most significantly increased miRNA. We validated decreased expression of miR-27b in DLBCL tissues, and we found that low expression of miR-27b was associated with poor overall survival of patients with DLBCL...
September 28, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29133623/immu-140-a-novel-sn-38-antibody-drug-conjugate-targeting-hla-dr-mediates-dual-cytotoxic-effects-in-hematological-cancers-and-malignant-melanoma
#8
Thomas M Cardillo, Serengulam V Govindan, Maria B Zalath, Diane L Rossi, Yang Wang, Chien-Hsing Chang, David M Goldenberg
HLA-DR is a member of the MHC class II antigen family expressed on hematological and solid tumors.  Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development.  IMMU-140 is an anti-HLA-DR antibody-drug conjugate comprised of the active metabolite of irinotecan, SN-38, conjugated to a humanized anti-HLA-DR IgG4 antibody (IMMU-114); the IgG4 naked antibody is devoid of immune functions. Our aim was to determine if SN-38, the metabolite of a drug not commonly used in hematopoietic cancers, would be effective and safe when targeted to HLA-DR-expressing tumors...
November 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29133193/prognostic-value-of-microrna-224-in-various-cancers-a-meta-analysis
#9
Yue Zhang, Cong-Cong Guo, Dong-Hui Guan, Chuan-Hua Yang, Yue-Hua Jiang
BACKGROUND: During previous studies, microRNA-224 (miR-224) was frequently investigated and discovered to be of vital significance to prognosis of patients with various cancers. However, its accurate prognostic value has not been estimated worldwide. Herein, we performed meta-analysis to assess its potential predictive value in a variety of human tumors. METHODS: Qualified researches were identified up to March 1, 2017 through performing online searches in PubMed, EMBASE, Web of Science and Cochrane Database of Systematic Reviews...
November 10, 2017: Archives of Medical Research
https://www.readbyqxmd.com/read/29132484/abdominal-ct-findings-in-patients-with-primary-lymphoma-causing-small-bowel-obstruction
#10
Elif Karadeli, Gurcan Erbay, Alper Parlakgumus, Hakan Yabanoglu
The purpose of this study was to investigate retrospectively CTfindings in patients with primary lymphoma causing small bowel obstruction. CTscans of 11 patients with small bowel lymphoma were separately analysed in terms of affected section of the small bowel, focality, wall thickness, pattern and degree of contrast enhancement, lymphadenopathy, organ involvement, perforation, and the presence of intraabdominal fluid. Eight patients had diffuse large B-cell lymphoma, and one patient each had marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), T-cell lymphoma, and anaplastic T-cell lymphoma...
November 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29131834/plasma-microrna-profiling-exploring-better-biomarkers-for-lymphoma-surveillance
#11
Drirh Khare, Neta Goldschmidt, Aya Bardugo, Devorah Gur-Wahnon, Iddo Z Ben-Dov, Batia Avni
Early detection of relapsed lymphoma improves response and survival. Current tools lack power for detection of early relapse, while being cumbersome and expensive. We searched for sensitive biomarkers that precede clinical relapse, and serve for further studies on therapy response and relapse. We recruited 20 healthy adults, 14 diffuse large B-cell lymphoma (DLBCL) patients and 11 Hodgkin lymphoma (HL) patients at diagnosis. Using small-RNA sequencing we identified in DLBCL patients increased plasma levels of miR-124 and miR-532-5p, and decreased levels of miR-425, miR-141, miR-145, miR-197, miR-345, miR-424, miR-128 and miR-122...
2017: PloS One
https://www.readbyqxmd.com/read/29130134/is-it-possible-to-improve-prognostic-value-of-nccn-ipi-in-patients-with-diffuse-large-b-cell-lymphoma-the-prognostic-significance-of-comorbidities
#12
Darko Antic, Jelena Jelicic, Goran Trajkovic, Milena Todorovic Balint, Jelena Bila, Olivera Markovic, Ivan Petkovic, Vesna Nikolic, Bosko Andjelic, Vladislava Djurasinovic, Aleksandra Sretenovic, Mihailo Smiljanic, Vojin Vukovic, Biljana Mihaljevic
The prognostic value of the International Prognostic Index (IPI) has been re-evaluated in the rituximab-treated diffuse large B cell lymphoma (DLBCL) patients. Accordingly, National Comprehensive Cancer Network-IPI (NCCN-IPI) has been introduced to estimate prognosis of DLBCL patients. However, comorbidities that frequently affect elderly DLBCL patients were not analyzed. The aim of this study was to evaluate the prognostic significance of comorbidities using Charlson Comorbidity Index (CCI) in 962 DLBCL patients...
November 12, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29128636/identification-of-key-micrornas-associated-with-diffuse-large-b-cell-lymphoma-by-analyzing-serum-microrna-expressions
#13
Yuanyuan Meng, Lina Quan, Aichun Liu
PURPOSE: This study aimed to investigate the molecular mechanism underlying diffuse large B-cell lymphoma (DLBCL). METHODS: Serum miRNA expression analysis for the serum samples of patients with DLBCL and those of controls was performed using the Illumina sequencing technology. Differentially expressed miRNAs (DEMs) were identified on the basis of the sequencing data. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and protein-protein interaction (PPI) network construction for the target genes of DEMs were also conducted...
November 8, 2017: Gene
https://www.readbyqxmd.com/read/29127587/copanlisib-first-global-approval
#14
Anthony Markham
Bayer are developing copanlisib (Aliqopa™)-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematological and solid malignancies. The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase II trial. Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or standard immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma...
November 10, 2017: Drugs
https://www.readbyqxmd.com/read/29126866/advances-in-diagnosis-and-management-of-diffuse-large-b-cell-lymphoma
#15
REVIEW
Fernando Cabanillas, Bijal Shah
The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. Although the reference standard for the identification of these cell types is considered gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC-based algorithms and their correlation with GEP and clinical outcome are discussed. Because of the adverse prognostic implications of the non-GCB type and its potential effects on treatment selection, the recently revised World Health Organization classification has included these biologic cell types...
November 7, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29126407/tp53-arg72-as-a-favorable-prognostic-factor-for-chinese-diffuse-large-b-cell-lymphoma-patients-treated-with-chop
#16
Yalu Liu, Xiaogan Wang, Ning Ding, Lan Mi, Lingyan Ping, Xuan Jin, Jiao Li, Yan Xie, Zhitao Ying, Weiping Liu, Chen Zhang, Lijuan Deng, Yuqin Song, Jun Zhu
BACKGROUND: TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown. METHODS: Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two hundred and eighty-nine patients were treated with R-CHOP, and 136 patients received CHOP or CHOP-like as frontline regimen. Three hundred and ninety-six patients were assessable for the efficacy...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29126177/cd30-expression-in-monomorphic-posttransplant-lymphoproliferative-disorder-diffuse-large-b-cell-lymphoma-correlates-with-greater-regulatory-t-cell-infiltration
#17
Christopher Hartley, James W Vaughan, Jason Jarzembowski, Steven H Kroft, Paul Hosking, Alexandra M Harrington, Horatiu Olteanu
Objectives: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling. Methods: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs...
November 8, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29125192/long-term-outcomes-among-2-year-survivors-of-autologous-hematopoietic-cell-transplantation-for-hodgkin-and-diffuse-large-b-cell-lymphoma
#18
Regina M Myers, Brian T Hill, Bronwen E Shaw, Soyoung Kim, Heather R Millard, Minoo Battiwalla, Navneet S Majhail, David Buchbinder, Hillard M Lazarus, Bipin N Savani, Mary E D Flowers, Anita D'Souza, Matthew J Ehrhardt, Amelia Langston, Jean A Yared, Robert J Hayashi, Andrew Daly, Richard F Olsson, Yoshihiro Inamoto, Adriana K Malone, Zachariah DeFilipp, Steven P Margossian, Anne B Warwick, Samantha Jaglowski, Amer Beitinjaneh, Henry Fung, Kimberly A Kasow, David I Marks, Jana Reynolds, Keith Stockerl-Goldstein, Baldeep Wirk, William A Wood, Mehdi Hamadani, Prakash Satwani
BACKGROUND: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for ≥2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10...
November 10, 2017: Cancer
https://www.readbyqxmd.com/read/29123411/increased-histone-deacetylase-6-expression-serves-as-a-favorable-prognostic-factor-for-diffuse-large-b-cell-lymphoma
#19
Xiao-Ji Lin, Li-Meng Cai, Zi-Jun Qian, Chen-Yi Wang, Ni Sun, Xiao-Hai Sun, He Huang, Wen-Jian Guo, Hai-Yan Lin, Rong-Xin Yao
Objective: This study aims to investigate ectopic expression of histone deacetylase 6 (HDAC6) in diffuse large B-cell lymphoma (DLBCL). Methods: This study analyzed patients with DLBCL (n=132) and reactive lymph node hyperplasia (n=32) diagnosed in our hospital from December 2007 to May 2016. Correlation between HDAC6 expression and clinical pathologic features was analyzed by χ(2) test. The significant differences between the 5-year overall survival (OS) or progression-free survival (PFS) and high HDAC6 expression as well as DLBCL clinic-pathological features including age, International Prognostic Index (IPI) score, Eastern Cooperative Oncology Group score, lactate dehydrogenase (LDH), and germinal center B-cell-like were assessed by univariate and multivariate analyses...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29122656/programmed-death-1-ligands-pd-l1-and-pd-l2-show-distinctive-and-restricted-patterns-of-expression-in-lymphoma-subtypes
#20
Poonam K Panjwani, Vivek Charu, Monique DeLisser, Hernan Molina-Kirsch, Yasodha Natkunam, Shuchun Zhao
The success of immunotherapy using immune checkpoint blockade in solid tumors and in relapsed/refractory classical Hodgkin lymphoma and chronic lymphocytic leukemia holds promise for targeted therapy in hematologic malignancies. Since efficacy of immunomodulatory therapy is correlated with numbers of cells that express programmed death (PD-1) ligands, we evaluated the expression of PD-L1 and PD-L2 proteins using immunohistochemistry in over 702 diagnostic lymphoma biopsies. In classical Hodgkin lymphoma, PD-L1 and PD-L2 were expressed in 82% and 41% of cases respectively, and PD-L1 but not PD-L2 expression correlated with Epstein Barr Virus in tumor cells...
November 6, 2017: Human Pathology
keyword
keyword
4131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"